Krystal Biotech, Inc. (KRYS) Dividend History

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for dermatological and rare diseases. Established with the goal of advancing genetic medicine, it utilizes a proprietary viral vector platform to deliver gene therapies with the potential to treat conditions that have limited treatment options. The company's approach aims to provide targeted, durable treatments for patients suffering from various skin disorders and other genetic conditions.

2100 Wharton Street, Pittsburgh, PA, 15203
Phone: (412) 586-5830
Website: https://www.krystalbio.com

Dividend History

Krystal Biotech, Inc. currently does not pay dividends

Company News

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech's gene therapy VYJUVEK has been approved by the European Commission for the treatment of dystrophic epidermolysis bullosa, a rare genetic skin disorder. The approval allows for flexible dosing and administration options.

GlobeNewswire Inc.
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Krystal Biotech reported strong financial results for Q4 and full year 2024, driven by the commercial success of its gene therapy VYJUVEK. The company also provided updates on its pipeline, including progress in respiratory, oncology, and aesthetics programs.

GlobeNewswire Inc.
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Jeune Aesthetics, a subsidiary of Krystal Biotech, announced the appointment of Nishant Saxena as its new Chief Financial Officer. Saxena brings extensive experience in life sciences, capital markets, and finance to his new role.

GlobeNewswire Inc.
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

The article discusses the prevalence and impact of rare genetic disorders, which affect over 350 million people worldwide. It highlights the challenges in treating these conditions, including limited treatment options and underfunding for research. The article also provides an overview of the market analysis for various rare genetic disorders, including Usher Syndrome, Alport Syndrome, Menkes Disease, and others.

GlobeNewswire Inc.

Featured Companies: AMGN BEAM HRMY RARE SWTX WVE
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Krystal Biotech's inhaled KB707 demonstrated early evidence of monotherapy activity in patients with advanced non-small cell lung cancer, with an objective response rate of 27% and disease control rate of 73%.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 15:04:45 UTC